Aquestive TherapeuticsAQST
AQST
About: Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Employees: 142
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
59% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 29
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
47% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 19
6% more funds holding
Funds holding: 114 [Q4 2024] → 121 (+7) [Q1 2025]
2.82% less ownership
Funds ownership: 47.57% [Q4 2024] → 44.76% (-2.82%) [Q1 2025]
15% less capital invested
Capital invested by funds: $154M [Q4 2024] → $131M (-$23.6M) [Q1 2025]
58% less call options, than puts
Call options by funds: $391K | Put options by funds: $923K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
105%
upside
Avg. target
$8.50
149%
upside
High target
$10
192%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Andreas Argyrides | 105%upside $7 | Outperform Assumed | 2 Jun 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 192%upside $10 | Buy Reiterated | 15 May 2025 |
Financial journalist opinion
Positive
Seeking Alpha
6 days ago
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share
Aquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm's advantages—wallet portability, rapid onset, and high patient/provider preference—position it to capture significant share of a $2B U.S. market. My risk-adjusted DCF analysis values AQST at $5/share ( at just 10% market share), indicating the stock is undervalued at current levels.
Neutral
Seeking Alpha
1 month ago
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Stanley Kristen Kluska - Cantor Fitzgerald Jason Butler - Citizens JMP Raghuram Selvaraju - HC Wainwright Dennis Resnick - Raymond James Nelson Cox - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Aquestive Therapeutics First Quarter 2025 Earnings Conference Call.
Neutral
Zacks Investment Research
1 month ago
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Negative
Zacks Investment Research
1 month ago
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2025, and provided a strategic business update.
Positive
Seeking Alpha
1 month ago
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential
AQST's Anaphylm, a sublingual epinephrine film, shows strong potential with FDA approval expected in Q2'25 and a $1B annual revenue target. AQST's financial health is weaker compared to competitors, with a probable need to raise $100M-$150M in the next 2-3 years. My base-case DCF model estimates a fair value of $8.11, offering a 179% upside, with an optimistic scenario reaching $15.38.
Neutral
GlobeNewsWire
1 month ago
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2025 and provide an update on recent developments in its business after market close on Monday, May 12, 2025.
Neutral
GlobeNewsWire
2 months ago
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the Piper Sandler Spring Biopharma Symposium in Boston. The Aquestive team will host investor meetings at the event on April 17.
Positive
Seeking Alpha
2 months ago
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy
Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mired in litigation. Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential.
Neutral
Seeking Alpha
3 months ago
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants David Amsellem - Piper Sandler Francois Brisebois - Oppenheimer Kristen Kluska - Cantor Fitzgerald Jason Butler - JMP Securities Raghuram Selvaraju - HC Wainwright & Co. Gary Nachman - Raymond James Thomas Flaten - Lake Street Capital Markets James Molloy - Alliance Global Partners Operator Good day, and thank you for standing by. Welcome to the Fourth Quarter 2024 Aquestive Therapeutics Earnings Conference Call.
Charts implemented using Lightweight Charts™